[PRNewswire] MGI and Bio-Medical Science Sign MOU
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"This MOU marks a key milestone for the development of genomics in South Korea as we introduce localized, high-quality and cost-effective solutions powered by our proprietary DNBSEQ™ technology." said Roy Tan, General Manager of MGI Asia Pacific. "By joining forces with our partner BMS, MGI aims to facilitate more widespread adoption of genomics, multi-omics, metagenomics and related business locally in South Korea."
"Amidst a rapidly growing high-throughput sequencing market in South Korea, we are noticing a mismatch between demand and supply and hope to eliminate access barriers by bringing products and solutions that are proven efficient, convenient and suited for local needs," said Kangsan D. Kim, Director of Marketing & Communications at BMS. "We are excited to partner with [PRNewswire] MGI to speed up the localization of their cutting-edge genomics products, especially sequencers such as DNBSEQ-G99."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
-- Delivers Cutting-Edge Sequencing Platforms and Reagents to South Korea
CHEONAN, South Korea 15 September 2023 /PRNewswire=연합뉴스/ -- MGI, a company committed to building core tools and technology to lead life science, today announced MOU with Bio-Medical Science Co., Ltd. ("BMS") to expand genomics solutions in South Korea by leveraging MGI's cutting-edge technology. The MOU is expected to reach collaborations in localizing MGI's manufacturing capability in selected genetic sequencers and reagents in South Korea via BMS, which will provide the market with state-of-the-art products that have been adapted to local needs, thereby helping advance genomic research and clinical diagnostics.
"This MOU marks a key milestone for the development of genomics in South Korea as we introduce localized, high-quality and cost-effective solutions powered by our proprietary DNBSEQ™ technology." said Roy Tan, General Manager of MGI Asia Pacific. "By joining forces with our partner BMS, MGI aims to facilitate more widespread adoption of genomics, multi-omics, metagenomics and related business locally in South Korea."
Under the MOU, BMS and MGI will work to reach collaborations relating to the licensing, supply, manufacturing and distribution of selected genetic sequencers and reagents in South Korea. Leveraging BMS' strong local network for sales and distribution and MGI's innovative technology, South Korea is set to further tap into the potential of larger scale genomics, clinical studies and even microbiome.
"Amidst a rapidly growing high-throughput sequencing market in South Korea, we are noticing a mismatch between demand and supply and hope to eliminate access barriers by bringing products and solutions that are proven efficient, convenient and suited for local needs," said Kangsan D. Kim, Director of Marketing & Communications at BMS. "We are excited to partner with [PRNewswire] MGI to speed up the localization of their cutting-edge genomics products, especially sequencers such as DNBSEQ-G99."
In fact, the relationship between MGI and BMS can be traced back to 2019, when BMS became the first company in Asia Pacific to join MGI's Global Sequencer User Program (SUP) to promote the development of genetic technologies and applications through customized products and services. Earlier this year, the two companies also partnered to establish a joint Customer Experience Center (CEC) in South Korea, aiming to provide local customers with first-hand access to MGI's newer technologies and products.
About MGI
MGI Tech Co., Ltd. (or its affiliates, "MGI"), headquartered in Shenzhen, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production, and sales of sequencing instruments*, reagents*, and related products to support life science research, agriculture, precision medicine and healthcare. As of June 30, 2023, MGI has more than 2,800 employees, and 35.2% of whom are R&D personnel. Founded in 2016, MGI operates in more than 90 countries and regions, serving more than 2,400 customers. For more information, please visit the MGI website [https://en.mgi-tech.com/ ] or connect on Twitter [https://twitter.com/MGI_Technology ], LinkedIn [https://www.linkedin.com/company/mgi-tech688114/posts/?feedView=all&viewAsMember=true ] or YouTube [https://www.youtube.com/channel/UCKKPhGZqnAapvrt-RZ3kwig ].
About BMS
Bio-Medical Science Co. Ltd., commonly referred to as BMS, holds a prominent position in the Korean life science distribution sector. Established in 1988, its headquarter is strategically based in Gangnam, Seoul, with a network of branches and a dedicated logistics distribution center spanning the nation. Its esteemed clientele encompasses major academic and governmental institutions, along with renowned research and diagnostics centers.
*Products are provided for Research Use Only. Not for use in diagnostic procedures (except as specifically noted)
Source: MGI Tech Co., Ltd.
CONTACT: MGI PR manager, Liu Wenhui, email:liuwenhui1@mgi-tech.com
[편집자 주] 이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 男 육아휴직 70%, 女 경력단절 10%…'쌍끌이'로 저출생 극복한다 | 연합뉴스
- 여야, 강대강 예산대치…"감액안 철회 먼저" "증액안 가져와야" | 연합뉴스
- 탄핵 표결 D-1…중앙지검장, 대행체제 대비 확대부장회의 소집 | 연합뉴스
- 한총리 "한미, 주요국 중 내년 최고 성장률…추경할 단계 아냐" | 연합뉴스
- [속보] 中 "갈륨 등 이중용도 품목 美수출 통제" | 연합뉴스
- 오세훈 "명태균·강혜경 검찰 고소" 법적대응…"맞서 싸울 것"(종합) | 연합뉴스
- 수요일도 계속 춥다…서울 체감온도 아침 -4도·낮 1도 | 연합뉴스
- 디딤돌대출 축소 본격화…내년 하반기 입주땐 잔금대출 불가 | 연합뉴스
- 대한항공, 오는 11일 아시아나 자회사로 편입…지분 63.9% 취득 | 연합뉴스
- 잘린 전선 무게 못이긴 개성공단 송전탑 와르르…인부 추락도 | 연합뉴스